Philips and Illumina join forces to offer integrated genomics solutions for oncology

Profiling tumors using genomic information is critical for complex cancer cases, and next-generation DNA sequencing – the process of rapidly profiling large sections of the genome in parallel to find mutations – is increasingly being used for this. However, challenges remain in developing ways to rapidly and accurately interpret genomic findings in the context of a patient's condition. While cancer patients can have hundreds of gene variants in their tumors, only a small number may actually drive the individual's specific cancer or may have actionable therapeutic implications for a particular patient. The patient's history, related lab tests and cancer type are needed for a meaningful interpretation of the genomic data.

Philips and Illumina will collaborate to provide new solutions aimed at the acquisition, analysis, annotation and interpretation of genomics data in oncology cases. The data will be acquired by Illumina's BaseSpace^®  Sequence Hub connected to its instruments and will be processed through Philips' IntelliSpace Genomics solution for oncology. This solution will combine data from multiple sources — radiology, immunohistochemistry, digital pathology, medical records and lab tests — and will deliver a consolidated dashboard view. This system will support researchers to develop insights more efficiently and will ultimately support lowering the cost of health care delivery and improved health outcomes.

"The value of genomic information for personalized care, and for the treatment of patients with cancer in particular, is tremendous," said Jeroen Tas, CEO of Connected Care and Health Informatics at Philips. "Until now the ability to use genomic data with the aim of having a precise diagnosis of cancer and improve treatment was mostly for the domain of academic centers. Through this collaboration we will unlock the value of genomics for a much wider group of laboratories and care providers to help them advance genomics initiatives at greater speed with the aim to offer precision medicine with better outcomes for their patients."

"We believe that this collaboration will provide an excellent path for our next-generation sequencing systems to be incorporated into health systems in the U.S. and worldwide," said Francis deSouza, President and CEO of Illumina. "One key strategy in our commitment to improving human health is connecting genomics to the everyday business of healthcare: based on integrated patient data, embedded into clinical pathways, supported by real-world evidence and reimbursement models."

The two companies intend to collaborate on system integration, cohort analysis and health economics applications, and future research programs. Laboratories adopting the solution will be able to integrate sequencing data with information from multiple data sources (e.g., imaging, pathology and laboratory). The Illumina-Philips solution will also give them ready access to advanced analytics, deep learning technologies and available reference literature, guidelines, and evidence in a single view.

IntelliSpace Genomics is powered by Philips HealthSuite, a secure, cloud-enabled ecosystem of systems, clinical applications and digital tools that gives access to advanced capabilities such as universal big data management, predictive analytics, artificial intelligence and Internet of Things (IoT) to support clinicians in first-time-right decision support. This enables Philips IntelliSpace Genomics to deliver real-time, actionable information to physicians and specialists for therapy planning, across locations.

BaseSpace^® Sequence Hub is a cloud-based platform that seamlessly extends Illumina instruments for the acquisition and analysis of genomic data, and managing sequencing runs and Illumina sequencing platforms to optimize operations. It enables the sharing of genomic data with a broad range of value-added Illumina and ecosystem analysis applications.

For Research Use Only.  Not for use in diagnostic procedures.

For further information, please contact:

Steve Klink
Philips Group Communications
Tel.: +31 6 10888824
E-mail: [email protected]

Kathy O'Reilly
Philips Group Communications
Tel: +1 978-221-8919
E-mail: [email protected] 
Twitter: @kathyoreilly

About Royal Philips
Royal Philips (NYSE: PHG, AEX: PHIA) is a leading health technology company focused on improving people's health and enabling better outcomes across the health continuum from healthy living and prevention, to diagnosis, treatment and home care. Philips leverages advanced technology and deep clinical and consumer insights to deliver integrated solutions. Headquartered in the Netherlands, the company is a leader in diagnostic imaging, image-guided therapy, patient monitoring and health informatics, as well as in consumer health and home care. Philips' health technology portfolio generated 2015 sales of EUR 16.8 billion and employs approximately 70,000 employees with sales and services in more than 100 countries. News about Philips can be found at www.philips.com/newscenter

About Illumina
Illumina is improving human health by unlocking the power of the genome. Our focus on innovation has established us as the global leader in DNA sequencing and array-based technologies, serving customers in the research, clinical, and applied markets. Our products are used for applications in the life sciences, oncology, reproductive health, agriculture, and other emerging segments. To learn more, visit www.illumina.com and follow @illumina.

SOURCE Royal Philips